Autonomix Medical announced it received a new U.S. patent for its catheter-based technology that captures and processes physiological signals near the biological source. This innovation enhances high-resolution sensing and real-time monitoring, potentially improving precision nerve-targeted treatments across multiple clinical applications like cardiovascular and pain management. The patent strengthens Autonomix's intellectual property as it advances its development programs and explores broader medical uses. The technology remains investigational and is not yet approved for marketing in the U.S.
Autonomix Medical's new U.S. patent for catheter-based sensing technology provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 11, 2026 01:11 WIB: out of 150 priced health-sector US stocks, 39 rose and 110 fell. Notable movers include BNGO at USD 1.30 with a 12.07% increase and 100% buy order activity, ACAD at USD 17.98 up 8.97% with 71% buy orders, and CRSP at USD 45.74 down 8.59% with 99% sell orders.
Auburn National Bancorporation, Inc. announced a quarterly cash dividend of $0.27 per share, payable on December 28, 2026, to shareholders recorded by December 10, 2026. The company is the parent of AuburnBank, an Alabama state-chartered bank with ab...
OpenTable's 2027 Quebec dining trends report shows a 9% increase in restaurant bookings, with 65% of Quebecers planning to dine out as much or more in 2027. Consumers prioritize value, local favorites, and meaningful experiences, often celebrating sm...
Pepeto's crypto presale is close to selling out, having raised $11.29 million with over 43,000 holders, driven by its fee-free trading platform and AI contract checks. Meanwhile, XRP's price has dropped to $1.11, down 72% from its peak, but analysts ...
YieldMax ETFs declared weekly distributions for their Group 1 ETFs, with distribution rates ranging from about 20% to 60% annually, depending on the ETF. These distributions reflect income generated primarily from options strategies and vary signific...
EssilorLuxottica disclosed its share capital and voting rights as of October 31, 2026, reporting 464,247,548 shares outstanding and 458,376,127 real voting rights excluding treasury shares. The company applies a 31% cap on voting rights per sharehold...
